LL-37
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.
Host-defense peptide used for antimicrobial, biofilm, wound-healing, gut-inflammation, and immune-dysfunction experiments when there is a real infection, wound, gut, or immune target.
LL-37 is context-dependent — anti-inflammatory in deficiency and infection states but potentially pro-inflammatory in active autoimmune disease or cancer; do not use during an active autoimmune flare.
Host-defense peptide used for antimicrobial, biofilm, wound-healing, gut-inflammation, and immune-dysfunction experiments when there is a real infection, wound, gut, or immune target.
Expect more injection-site irritation than with BPC-157, plus possible early flu-like fatigue, lymph-node tenderness, and appetite changes. The serious boundary is context: active autoimmune disease or cancer can turn LL-37's immune effects in the wrong direction, and systemic SubQ use has no formal human safety dataset.
LL-37 occupies a distinct niche: the only community peptide that addresses both the antimicrobial and immunomodulatory dimensions of infection and inflammation simultaneously. BPC-157 heals tissue; LL-37 defends it. For users with chronic infections, biofilm-protected pathogens, or immune dysfunction, it fills a gap no other community peptide covers.
High community signal only when the indication is well-matched: chronic infection, wound risk, suspected biofilm, gut dysbiosis, or immune-deficiency logic. The strongest clinical signal is topical wound healing, while systemic SubQ use remains extrapolated. Non-response is estimated at 15–25% and is most often attributed to low vitamin D, degraded peptide, or using LL-37 without an active infection, wound, gut, or immune target.
Do not combine LL-37 with active immunosuppressive therapy (biologics, systemic corticosteroids, methotrexate) — the immunostimulatory mechanism directly opposes immunosuppression and the combination creates unpredictable outcomes.
Intro
LL-37 is a 37-amino acid cationic antimicrobial peptide — the only cathelicidin expressed in humans.
It is derived from the C-terminus of the hCAP-18 precursor protein by proteolytic cleavage (kallikrein, proteinase 3). The name 'LL-37' reflects its length (37 residues) and N-terminal double leucine. Gene: CAMP (Cathelicidin Antimicrobial Peptide), chromosome 3. Production sites: neutrophils, epithelial cells of skin, lung, gut, and urogenital tract, mast cells, NK cells, and monocytes.
LL-37's primary mechanism is amphipathic alpha-helix membrane disruption. In aqueous solution, LL-37 is a random coil; on contact with bacterial or viral lipid membranes, it adopts a cationic amphipathic helix, inserts electostatically into the membrane (net +6 charge targeting negatively charged microbial lipids), and disrupts membrane integrity by toroidal pore formation or the carpet mechanism. Beyond direct killing, LL-37 modulates the immune response via formyl peptide receptor 2 (FPR2/FPRL1) — recruiting neutrophils, monocytes, and T cells; maturing dendritic cells; suppressing TLR4-mediated LPS signaling (anti-endotoxin effect); and activating keratinocyte EGFR/MAPK for wound healing.
LL-37 is unique in humans as a non-redundant innate immune defense peptide. It sits at the intersection of antimicrobial killing, immunomodulation, wound repair, and adaptive immune priming. Endogenous expression is tightly regulated by the vitamin D axis: vitamin D3 binding to the vitamin D receptor (VDR) directly induces the CAMP gene. This makes vitamin D status the most important modifiable factor in LL-37 pharmacology — vitamin D deficiency directly reduces innate mucosal defense by suppressing CAMP/LL-37 expression.
Community use is based on a mechanistically coherent extrapolation: if endogenous LL-37 defends against infection and heals wounds, exogenous supplementation during deficiency states, chronic infection, or immune dysfunction should augment these effects. The clinical evidence base is primarily topical wound healing and in vitro antimicrobial/immunomodulatory data. The community is using the systemic SubQ route without formal pharmacokinetic or safety data for this route — the honest framing is 'mechanistic rationale extrapolated from wound-care clinical trials to systemic injection.'
LL-37 is not a physique or performance compound. It occupies a specialized niche alongside KPV and Thymosin Alpha-1 in the immune and wound-healing category of community peptides.
Observed Effects
Wound healing acceleration is the most clinically supported effect: a diabetic foot ulcer RCT (Springer 2023) demonstrated statistically significant reduction in wound size at 8 weeks vs.
placebo with topical LL-37. Community-reported wound healing outcomes (50–68% ulcer area reduction) exceed controlled trial numbers, likely reflecting reporting bias and different populations. The mechanism is EGFR transactivation via MAPK pathway driving keratinocyte proliferation and collagen remodeling.
Reduced infection frequency and faster recovery from active illness is the dominant community-reported benefit for immune applications. Community users with chronic sinusitis report reduced infection frequency (one user: 4–5 sinus infections/year to 1 post-cycle). Faster recovery from active infection mid-cycle is also commonly reported. This is consistent with the FPR2-mediated neutrophil recruitment and mucosal defense enhancement mechanism, though confounded by seasonal variation and multi-compound protocols.
Biofilm disruption in chronic infection is the most mechanistically compelling niche: in vitro evidence demonstrates that LL-37 penetrates and disrupts established biofilms (Pseudomonas, Staphylococcus, dental). Community anecdote: one user combined LL-37 + doxycycline for chronic periodontitis and reported faster resolution vs. prior antibiotic courses. Biofilm-protected pathogens resist conventional antibiotics but remain susceptible to LL-37's physical membrane disruption — making this application uniquely suited to LL-37.
Gut inflammation reduction is documented in animal IBD models (NF-κB suppression) with community self-report supporting approximately 50% response rates in IBD/SIBO/leaky gut users over 4–8 weeks. Non-response is attributed to absence of an active pathogen target or low vitamin D limiting effectiveness.
Immune normalization in autoimmune and post-biologic contexts is supported by first-person community reports but not clinical data. Ketogenichealth Substack (post-Humira): 'LL-37 helped me feel like my immune system was working again without pharmacological suppression.' Brooke Bowman Substack: autoimmune fatigue, brain fog, and joint pain improvement described as meaningful but partial in a multi-compound protocol. Confounders are significant in these reports.
Antiviral activity against enveloped viruses (influenza, herpes, SARS-CoV-2) is demonstrated in vitro via direct membrane disruption of viral envelopes. Post-COVID community use is common but remains mechanistic extrapolation — no controlled human antiviral data exists.
Important caveat: LL-37 has context-dependent and dose-dependent anti- vs. pro-tumorigenic effects in cancer models — anti-tumorigenic in colon cancer but potentially pro-tumorigenic in ovarian and lung cancer contexts by promoting angiogenesis. This is in vitro only but warrants caution.
Field Reports
Community reports are strongest when LL-37 is attached to a specific immune, wound, gut, infection, or biofilm target rather than used as a vague wellness peptide.
Multi-peptide autoimmune-fatigue and post-biologic anecdotes describe improved energy, cognitive clarity, and immune normalization, but they are heavily confounded by other interventions and cannot isolate LL-37 as the cause. Public infection threads include reports of fewer sinus or respiratory infections after a cycle, while dental/biofilm anecdotes describe faster gum healing when combined with standard dental or antimicrobial care. Aggregated guide reports describe increased energy, faster wound/abrasion healing, and improved immune resistance perception within days 3-7, with a 15-25% non-response rate usually attributed to low vitamin D, degraded peptide, or poor indication fit. Side effects commonly include injection-site redness/swelling, sleep disruption when dosed late, appetite changes, transient fever/flu-like symptoms, and lymph-node tenderness. Long-COVID and ME/CFS reports are mixed, with some users improving and others worsening, plausibly from immune overstimulation.
Community Consensus
The community consensus is bullish but bounded: LL-37 is treated as a specialized immune-defense tool, not a general wellness peptide.
The common shorthand is 'the immune system's own antibiotic,' but experienced users add the missing half of the story: FPR2 signaling, dendritic-cell activation, LPS neutralization, wound repair, and immune-context dependence matter as much as direct antimicrobial membrane disruption.
Three use populations dominate the discussion. Wound and tissue-healing users apply it when infection risk or slow closure is part of the problem. Immune-dysfunction users apply it around recurrent infections, post-biologic transitions, post-COVID dysregulation, ME/CFS, and chronic illness patterns, with more variance and more caution. Gut users apply it around IBD, SIBO, leaky gut, post-antibiotic dysbiosis, and gut-reset protocols where infection or dysbiosis is suspected.
The practical consensus separates LL-37 from KPV and BPC-157 by job. LL-37 is favored when infection, biofilm, or immune-defense failure is plausible. KPV is favored when the problem is mainly inflammatory and the user wants less immune activation. BPC-157 is the dominant stack partner because the pairing has a clear division of labor: BPC-157 pushes tissue repair while LL-37 adds antimicrobial and immune-defense coverage.
The skeptical side is also coherent. LL-37 has a smaller user base than BPC-157, TB-500, or GH-axis peptides; the strongest clinical data is topical wound care; and systemic SubQ protocols are community extrapolation. Experienced users often acknowledge that gap directly, which makes the positive consensus narrower but more useful: run it for a targetable immune, wound, gut, infection, or biofilm problem, not because it sounds broadly regenerative.
Monitoring consensus is unusually strong for a community peptide. Baseline 25-OH vitamin D is treated as the key prerequisite because the CAMP/VDR axis directly couples vitamin D status to endogenous LL-37 production. CBC and CRP are common context labs when infection, inflammatory disease, or immune activation is part of the reason for use.
Risks & Monitoring
Injection site reactions are the most common adverse effect (>10% of users) and more frequent than BPC-157 at equivalent volumes — attributed to LL-37's membrane-active mechanism causing local inflammation.
Presentation: redness, transient warmth, mild swelling, occasional bruising. Management in reports centers on site rotation, lowering local concentration, or stopping if reactions escalate.
Transient flu-like symptoms in days 1–3 (5–10% of users, self-limiting): mild fever, fatigue, and myalgia consistent with the innate immune activation mechanism. Acute FPR2-mediated immune stimulation produces transient systemic inflammatory signaling. Resolves without intervention by day 3–7 with continued dosing.
Lymph node tenderness in weeks 1–2 (10–15% of users): tenderness at regional lymph nodes, consistent with FPRL1-mediated dendritic cell activation and lymphocyte trafficking. Community frames this as 'immune system working' and it resolves within days to 1 week. Persistent or enlarging lymphadenopathy warrants medical evaluation.
Appetite and GI changes (20–30% of users): appetite changes in both directions — increased appetite at lower doses (possibly improved gut function and nutrient absorption) and decreased appetite at higher doses (cytokine-mediated anorexia). GI disruption during gut-reset protocols (loose stools, cramping days 1–7) is expected and framed by community as the mechanism working. Some users experience a herxheimer-like reaction (worsening before improvement, fatigue, brain fog, nausea) attributed to endotoxin release from dying bacteria, typically resolving by days 7–10.
Context-dependent pro-inflammatory risk (unknown frequency, potentially significant): in populations with dysregulated immune activation — uncontrolled autoimmune disease, psoriasis (where LL-37 forms complexes with self-DNA activating plasmacytoid dendritic cells), lupus, or active cancer — exogenous LL-37 may worsen rather than resolve inflammation. Some long-COVID users report worsening fatigue. This is not a hypothetical risk; in psoriasis and lupus it is a documented pathological mechanism.
Theoretical cancer risk at elevated concentrations (in vitro only): pro-tumorigenic effects in ovarian and lung cancer contexts by promoting angiogenesis and tumor cell migration. Not applicable at community doses per available evidence, but warrants monitoring in susceptible populations.
For Women
Monitoring Panels
REQUIRED is a real safety gate. RECOMMENDED is the prudent default. OPTIONAL covers symptoms, risk factors, or tighter tracking.
Vitamin D is the primary upregulator of endogenous LL-37 via the CAMP gene VDR axis. Deficiency directly limits effectiveness of both endogenous and exogenous LL-37. Target: 50–80 ng/mL before starting. Community consensus: vitamin D correction may be more cost-effective than LL-37 supplementation in severely deficient users.
Establish baseline white cell count and differential before immunostimulatory therapy. LL-37 drives neutrophil and monocyte recruitment; baseline neutropenia or pre-existing immune dysregulation changes the risk profile. Repeat post-cycle if lymph node symptoms or persistent fatigue develop.
Baseline inflammatory marker to contextualize any increases during the immune activation phase (days 1–7). Elevated baseline CRP may indicate an active inflammatory state where LL-37's pro-inflammatory risk is higher.
Kidney and liver function baseline for users running LL-37 in a multi-compound stack. No known direct hepatotoxicity or nephrotoxicity; included for general due diligence in longer cycles.
For users with personal or family history of autoimmune disease, LL-37's capacity to stimulate self-DNA immune responses makes ANA screening reasonable before starting. Not required for users without autoimmune history.
Avoid With
Do not combine LL-37 with the following. Sorted highest-severity first.
Why:LL-37 is an immunostimulant; biologics and immunosuppressives are pharmacological immune dampeners. Opposing mechanisms create unpredictable outcomes — the immunostimulatory LL-37 effect may be negated, or the combination may destabilize an autoimmune condition that is currently controlled.
What to do:Users transitioning off biologics may eventually use LL-37, but not concurrently. Medical supervision required for any use near biologic therapy.
Why:In psoriasis and lupus specifically, LL-37 forms complexes with self-DNA that activate plasmacytoid dendritic cells — a known driver of these disease pathologies. Using LL-37 during an active autoimmune flare risks worsening the inflammatory cascade.
What to do:LL-37 may be appropriate in stable autoimmune disease (between flares, off biologics) with medical supervision — not during active disease.
Why:LL-37 has context-dependent effects on tumor cells — pro-tumorigenic in some cancer types by promoting angiogenesis and tumor cell migration via EGFR activation. No human data on exogenous LL-37 in cancer patients.
What to do:Colon cancer appears to be an exception (anti-tumorigenic in vitro). Still insufficient data to recommend use in any active cancer context.
Protocols By Goal
Chronic infection / recurring infections: reports commonly use 100-125 mcg/day for 50-60 days with vitamin D optimization and careful monitoring for early immune activation.
This is the strongest community-supported use case, but still extrapolated from topical and mechanistic evidence.
Wound healing / tissue repair: community protocols often pair LL-37 with BPC-157 when infection risk and tissue repair overlap. For accessible wounds, topical clinical evidence is stronger than systemic injection extrapolation.
Gut health: protocol guides discuss 100-125 mcg/day for several weeks around IBD, SIBO, leaky gut, or post-antibiotic dysbiosis, but early GI disruption can reflect either transient immune activation or true worsening.
Immune augmentation: post-viral, post-biologic, and chronic-illness users tend to use conservative dosing and separate LL-37 from other immune-active compounds so worsening fatigue or flare signals are interpretable.
Dosing Details
Standard community practice clusters around 100-125 mcg/day SubQ, with 100-250 mcg/day described as the broader range and 50-day cycles appearing often.
Morning use is commonly preferred to reduce sleep disruption from immune activation. Cycles are usually 4-8 weeks with breaks afterward because long-term systemic safety data are absent. Reports often start at the low end to assess flu-like symptoms, lymph-node tenderness, and injection-site irritation before any escalation. Reconstitution math, dilution instructions, storage operations, and syringe-unit calculations are intentionally omitted from this public protocol field.
Stacks & Alternatives
The dominant community stack — 'repair and defend.' BPC-157 drives tissue regeneration via VEGF/TGF-β growth factor pathways; LL-37 provides antimicrobial protection and prevents re-infection while BPC-157 heals. Complementary, not redundant. Relevant for gut healing, wound healing, and any infectious-inflammatory context. Typical doses: BPC-157 500 mcg/day + LL-37 125–250 mcg/day.
Extended tissue repair stack. TB-500's actin-polymerization and cell migration mechanism adds a third dimension alongside BPC-157's growth factor activity and LL-37's immune defense. Used in complex wound or post-surgical recovery protocols. TB-500 2–5 mg twice weekly + LL-37 125 mcg/day.
Not a peptide — a pharmacological prerequisite. Vitamin D3 directly upregulates the CAMP gene encoding LL-37. Deficiency impairs exogenous LL-37 effectiveness. Target 50–80 ng/mL 25-OH vitamin D before and during use. Standard supplementation: 5,000–10,000 IU vitamin D3 + MK-7 K2 for the duration of the cycle.
Differentiated, sequential use case. LL-37 is preferred when infection or biofilm is present; KPV (alpha-MSH fragment, anti-inflammatory via melanocortin receptors) for purely inflammatory conditions without an active infectious component. In IBD with suspected SIBO or dysbiosis, LL-37 is more targeted. Sequential use — LL-37 for antimicrobial phase, KPV for post-clearance anti-inflammatory phase — is an advanced protocol.
Alternatives
Stack Cost
Moderate tax: LL-37 is low-cost and non-hormonal, but its immune-context dependence, autoimmune/cancer exclusions, vitamin D prerequisite, and systemic SubQ evidence gap make it more demanding than ordinary repair peptides.
The article's core safety concern is context-dependent immune activity: LL-37 can be anti-inflammatory in infection/deficiency states but pro-inflammatory in active autoimmune disease and potentially problematic in cancer contexts.
stackingConflicts marks active immunosuppressive therapy and active autoimmune flares as hard conflicts because LL-37's immunostimulatory mechanism can directly oppose or destabilize immune suppression.
recommendedPanels requires vitamin D as a prerequisite and suggests CBC, CRP, and autoimmune screening depending on history. This is more screening than BPC-style tissue repair but less than endocrine or oral-AAS monitoring.
The article stresses precise small-dose handling, daily SubQ injection, site rotation, and higher injection-site irritation than BPC-157.
The article describes LL-37 as inexpensive per 40-50 day cycle, but value is indication-dependent and poor when there is no immune, wound, gut, or infection target.
- ·Counts as an immune-modulation lane, not a hormonal, GH/IGF, stimulant, or hepatic lane.
- ·Do not run during active autoimmune flare, active cancer, suspected cancer, pregnancy, or concurrent biologic/systemic immunosuppressive therapy.
- ·Correct low vitamin D before starting; the article treats the CAMP/VDR axis as the major modifiable prerequisite.
- ·Use LL-37 when infection, biofilm, wound, gut dysbiosis, or immune-deficiency logic is present; use KPV or other anti-inflammatory tools when the problem is purely inflammatory.
- ·Escalate slowly from the standard 100-125 mcg/day range only after early immune-activation symptoms and injection-site tolerance are understood.
- ·Baseline 25-OH vitamin D with correction toward the article's 50-80 ng/mL target.
- ·CBC with differential and CRP/hsCRP when immune activation, chronic infection, or inflammatory disease is the target.
- ·ANA screening when personal or family autoimmune history exists.
- ·Daily site rotation and dilution adjustment if injection-site reactions are significant.
- ·Cold storage and handling accuracy
The article rates LL-37 intermediate to advanced: it is non-hormonal and inexpensive, but requires indication fit, vitamin D optimization, immune-context screening, and acceptance of thin systemic SubQ evidence.
- ·Using it as a general wellness peptide without a target indication
- ·Active lupus, psoriasis flare, RA flare, active IBD flare, or uncontrolled immune activation
- ·No ability to distinguish transient immune activation from worsening disease
- ·Unable to manage small-dose peptide handling accurately
No taper or hormonal recovery is needed, but immune activation can worsen before improving and autoimmune/cancer red flags require decisive discontinuation rather than protocol tinkering.
- ·Transient flu-like or lymph-node symptoms may take days to settle.
- ·Gut-reset users may have herxheimer-like symptoms that need differentiation from true worsening.
- ·Stopping may leave the original infection, wound, or dysbiosis target unresolved.
- ·Injection-site irritation may persist briefly after stopping.
Treat these as hard stops unless medically supervised; the article's LL-37/self-DNA mechanism makes flare amplification plausible.
Check 25-OH vitamin D before starting and correct deficiency first; the article treats VDR-driven CAMP expression as central to LL-37 biology.
Define the target outcome before the cycle and stop if there is no signal after a reasonable trial.
Hold or stop the protocol and reassess; not every inflammatory response is a useful herxheimer-like phase.
The article identifies LL-37/self-DNA or self-RNA immune complexes as a known pathological amplifier in these conditions.
The article notes context-dependent pro-tumorigenic effects in some cancer models and no human safety basis for exogenous use in cancer.
The immunostimulatory mechanism directly conflicts with immune suppression and may destabilize controlled disease.
The article's womenConsiderations flags immunological tolerance concerns and lack of pregnancy data.
Practical Setup
Vitamin D optimization is the highest-priority preparation step: 25-OH vitamin D is the key context marker because the CAMP gene is directly regulated by the vitamin D receptor.
Users with severe deficiency may benefit more from vitamin D correction than from exogenous LL-37. Injection site rotation matters because LL-37 has higher local-irritation rates than many repair peptides. Active autoimmune flare, biologic/systemic immunosuppressive therapy, active or suspected cancer, pregnancy, and conception attempts are red-flag contexts. CBC, CRP/hsCRP, and autoimmune screening are context-dependent markers when infection, inflammatory disease, or immune activation is part of the reason for use. If flu-like, lymph-node, gut-reset, or fatigue symptoms persist rather than settling, hold or stop rather than assuming every inflammatory response is beneficial.
Mechanism Deep Dive
Primary mechanism — amphipathic alpha-helix membrane disruption: LL-37 is a random coil in aqueous solution but adopts a cationic amphipathic alpha-helix on contact with microbial membranes.
Its net +6 charge at physiological pH drives electrostatic attraction to the negatively charged anionic phospholipid outer leaflets of bacterial and viral membranes. The helix inserts into the membrane lipid bilayer and disrupts its integrity via toroidal pore formation (LL-37 aggregates form toroidal lipid-protein pores that traverse the membrane) or the 'carpet' mechanism (detergent-like lateral disruption and dissolution). Both gram-positive and gram-negative bacteria are susceptible, as are enveloped viruses. The physical mechanism means LL-37 is effective against biofilm-protected organisms that resist conventional antibiotics.
Immunomodulatory mechanism — FPR2/FPRL1 signaling: beyond direct killing, LL-37 binds to formyl peptide receptor 2 (FPR2/FPRL1) on neutrophils, monocytes, NK cells, and dendritic cells. This drives chemotaxis of innate immune cells to sites of infection or injury, maturation of dendritic cells (enhancing antigen presentation and adaptive immune priming), and macrophage polarization toward anti-inflammatory phenotypes in resolution-phase contexts. Critically, LL-37 directly binds and neutralizes LPS (lipopolysaccharide) — reducing TLR4-mediated endotoxemia. This LPS-neutralizing activity may attenuate the herxheimer-like inflammatory surge during gut dysbiosis clearance.
Wound healing mechanism — EGFR/MAPK transactivation: LL-37 transactivates the epidermal growth factor receptor (EGFR) via MAPK signaling in keratinocytes, driving keratinocyte proliferation, directional migration, and collagen remodeling. Angiogenesis promotion via VEGF upregulation contributes to wound tissue revascularization. Bone and periodontal tissue regeneration via Wnt signaling and BMP-mediated pathways is documented in animal and early human studies.
Vitamin D regulatory axis — the CAMP gene contains a functional vitamin D response element (VDRE) directly activated by the vitamin D receptor (VDR) when bound to 1,25-dihydroxyvitamin D3. This is direct transcriptional regulation, not indirect. Population-level vitamin D deficiency (common at northern latitudes and in indoor lifestyles) produces chronically suppressed CAMP/LL-37 expression and reduced innate mucosal immunity as a direct consequence. This makes vitamin D status both the primary modifiable factor in endogenous LL-37 production and a potential limiting factor in exogenous LL-37 effectiveness.
Context-dependent anti- vs. pro-inflammatory balance: LL-37's inflammatory modulation is bidirectional. In infection/deficiency states (low endogenous LL-37, active microbial threat), LL-37 resolves inflammation by killing pathogens and driving immune responses toward resolution. In autoimmune-active states — psoriasis, lupus, rheumatoid arthritis — LL-37 is already elevated and participates in pathology. In psoriasis and lupus specifically, LL-37 forms complexes with self-DNA and self-RNA that activate plasmacytoid dendritic cells via TLR7/9, perpetuating the inflammatory cycle. The same peptide is anti-inflammatory in one context and a pathological amplifier in another — this is the core safety concern for community users.
Antithrombotic activity (Springer 2025, preclinical): LL-37 inhibits platelet aggregation and dissolves fibrin clots in preclinical models — a newly discovered activity with potential cardiovascular relevance. Clinical significance at community doses is unknown.
Evidence Index
Quantitative claims trace to these source studies. Population, dose, and study type matter — claims from HIV-lipodystrophy trials don't transfer cleanly to healthy adults; data from supraphysiologic doses doesn't apply at TRT.
Topical LL-37 produced statistically significant wound size reduction at 8 weeks vs. placebo in diabetic foot ulcer patients
Topical route only — direct extrapolation to SubQ systemic use requires assumption of equivalent tissue concentrations, which is unvalidated
LL-37 showed a favorable safety profile in Phase I clinical wound application
Phase I = safety focused, limited size. Topical route only.
LL-37 reduced NF-κB-mediated gut inflammation in animal IBD models
The gut healing community application is extrapolated from mechanistic animal evidence, not human clinical data
LL-37 disrupts established biofilms in Pseudomonas, Staphylococcus, and dental biofilm models
Strong mechanistic rationale but no confirmation that SubQ-dosed LL-37 achieves tissue concentrations sufficient for in vivo biofilm disruption
LL-37 exhibits antithrombotic properties by inhibiting platelet aggregation and dissolving fibrin clots in preclinical models
New finding (Springer 2025). Not yet replicated. Clinical significance at community doses unknown.
Not medical advice. PepTutor summarizes fallible research and community signal for trained practitioners; some compounds are research-only, unapproved, controlled, jurisdiction-dependent, or labeled not for human consumption.